Investors

Investors Overview

INVESTORS OVERVIEW

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Our core technology approach is based on the use of boron chemistry for our drug research and development initiatives.

AN2 Tower

PRESENTATIONS

There are no presentations available at this time.